Epirub may be available in the countries listed below.
Epirubicin hydrochloride (a derivative of Epirubicin) is reported as an ingredient of Epirub in the following countries:
International Drug Name Search
Addos may be available in the countries listed below.
Nifedipine is reported as an ingredient of Addos in the following countries:
International Drug Name Search
Funzela may be available in the countries listed below.
Fluconazole is reported as an ingredient of Funzela in the following countries:
International Drug Name Search
Fixopan may be available in the countries listed below.
Alendronic Acid sodium trihydrate (a derivative of Alendronic Acid) is reported as an ingredient of Fixopan in the following countries:
International Drug Name Search
Ciprolin may be available in the countries listed below.
Ciprofloxacin is reported as an ingredient of Ciprolin in the following countries:
International Drug Name Search
Aciphin may be available in the countries listed below.
Ceftriaxone is reported as an ingredient of Aciphin in the following countries:
International Drug Name Search
Morniflu may be available in the countries listed below.
Morniflumate is reported as an ingredient of Morniflu in the following countries:
International Drug Name Search
Citrate de Bétaïne Biogaran may be available in the countries listed below.
Betaine citrate (a derivative of Betaine) is reported as an ingredient of Citrate de Bétaïne Biogaran in the following countries:
International Drug Name Search
Ifapidin may be available in the countries listed below.
Ticlopidine hydrochloride (a derivative of Ticlopidine) is reported as an ingredient of Ifapidin in the following countries:
International Drug Name Search
Calcitugg may be available in the countries listed below.
Calcium Carbonate is reported as an ingredient of Calcitugg in the following countries:
International Drug Name Search
Cinarizinã may be available in the countries listed below.
Cinnarizine is reported as an ingredient of Cinarizinã in the following countries:
International Drug Name Search
Tretin may be available in the countries listed below.
Isotretinoin is reported as an ingredient of Tretin in the following countries:
Tretinoin is reported as an ingredient of Tretin in the following countries:
International Drug Name Search
Ior Leukocim may be available in the countries listed below.
Filgrastim is reported as an ingredient of Ior Leukocim in the following countries:
International Drug Name Search
Epoprostenol Sodium (BAN, USAN) is known as Epoprostenol in the US.
International Drug Name Search
Glossary
| BAN | British Approved Name |
| USAN | United States Adopted Name |
Temocapril Hydrochloride may be available in the countries listed below.
Temocapril Hydrochloride (BANM, JAN, USAN) is also known as Temocapril (Rec.INN)
International Drug Name Search
Glossary
| BANM | British Approved Name (Modified) |
| JAN | Japanese Accepted Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Gynostatin may be available in the countries listed below.
Nystatin is reported as an ingredient of Gynostatin in the following countries:
International Drug Name Search
Coffeinum Natrium Benzoicum may be available in the countries listed below.
Caffeine sodium benzoate (a derivative of Caffeine) is reported as an ingredient of Coffeinum Natrium Benzoicum in the following countries:
International Drug Name Search
Rivotril 0.5mg Tablets
Rivotril 2mg Tablets
Rivotril 0.5mg Tablets:
Each tablet contains 0.5mg clonazepam.
Excipients: Also contains 40mg lactose monohydrate.
Rivotril 2mg Tablets:
Each tablet contains 2mg clonazepam.
Excipients: Also contains 121.5mg lactose anhydrous.
For a full list of excipients, see section 6.1.
Tablets.
Rivotril 0.5mg Tablets:
Round, dull pinkish-buff tablets with 'ROCHE 0,5' imprinted on one face and a single break mark on the other.
The Tablets can be broken into equal halves to facilitate dosing.
Rivotril 2mg Tablets:
Round, white tablets with 'ROCHE ·2·' imprinted on one face and cross break marks on the other.
The tablets can be broken into equal halves or quarters to facilitate dosing.
Tablets: All clinical forms of epileptic disease and seizures in infants, children and adults, especially absence seizures (petit mal) including atypical absence; primary or secondarily generalised tonic-clonic (grand mal), tonic or clonic seizures; partial (focal) seizures with elementary or complex symptomatology; various forms of myoclonic seizures, myoclonus and associated abnormal movements.
The scored 0.5mg tablets facilitate the administration of lower daily doses in the initial stages of treatment.
Adults
Initial dosage should not exceed 1mg/day. The maintenance dosage for adults normally falls within the range 4 to 8mg.
Elderly
The elderly are particularly sensitive to the effects of centrally depressant drugs and may experience confusion. It is recommended that the initial dosage of Rivotril should not exceed 0.5mg/day.
These are total daily dosages which should be divided into 3 or 4 doses taken at intervals throughout the day. If necessary, larger doses may be given at the discretion of the physician, up to a maximum of 20mg daily. The maintenance dose should be attained after 2 to 4 weeks of treatment.
Infants and children
To ensure optimum dosage adjustment, children should be given the 0.5mg tablets.
Initial dosage should not exceed 0.25mg/day for infants and small children (1 to 5 years) and 0.5mg/day for older children. The maintenance dosage normally falls within the ranges:
|
|
|
|
|
|
In some forms of childhood epilepsy, certain patients may cease to be adequately controlled by Rivotril. Control may be re-established by increasing the dose, or interrupting treatment with Rivotril for 2 or 3 weeks. During the interruption in therapy, careful observation and other drugs may be needed.
Mode of administration
Treatment should be started with low doses. The dose may be increased progressively until the maintenance dose suited to the individual patient has been found.
The dosage of Rivotril must be adjusted to the needs of each individual and depends on the individual response to therapy. The maintenance dosage must be determined according to clinical response and tolerance.
The daily dose should be divided into 3 equal doses. If doses are not equally divided, the largest dose should be given before retiring. Once the maintenance dose level has been reached, the daily amount may be given in a single dose in the evening.
Simultaneous administration of more than one antiepileptic drug is a common practice in the treatment of epilepsy and may be undertaken with Rivotril. The dosage of each drug may be required to be adjusted to obtain the optimum effect. If status epilepticus occurs in a patient receiving oral Rivotril, intravenous Rivotril may still control the status. Before adding Rivotril to an existing anticonvulsant regimen, it should be considered that the use of multiple anticonvulsants may result in an increase of undesired effects.
Patients with known sensitivity to benzodiazepines; or any of the drugs excipients; acute pulmonary insufficiency; severe respiratory insufficiency, sleep apnoea syndrome, myasthenia gravis, severe hepatic insufficiency.
Suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents in several indications. A meta-analysis of randomised placebo controlled trials of anti-epileptic drugs has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for clonazepam.
Therefore patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge.
Patients with a history of depression and/or suicide attempts should be kept under close supervision.
Rivotril should be used with caution in patients with chronic pulmonary insufficiency, or with impairment of renal or hepatic function, and in the elderly or the debilitated. In these cases dosage should generally be reduced.
As with all other antiepileptic drugs, treatment with Rivotril even if of short duration, must not be abruptly interrupted, but must be withdrawn by gradually reducing the dose in view of the risk of precipitating status epilepticus. This precaution must also be taken when withdrawing another drug while the patient is still receiving Rivotril therapy.
Prolonged use of benzodiazepines may result in dependence development with withdrawal symptoms on cessation of use.
Rivotril may be used only with particular caution in patients with spinal or cerebellar ataxia, in the event of acute intoxication with alcohol or drugs and in patients with severe liver damage (e.g. cirrhosis of the liver).
Rivotril should be used with extreme caution in patients with a history of alcohol or drug abuse.
In infants and small children Rivotril may cause increased production of saliva and bronchial secretion. Therefore special attention must be paid to maintaining patency of the airways.
The dosage of Rivotril must be carefully adjusted to individual requirements in patients with pre-existing disease of the respiratory system (e.g. chronic obstructive pulmonary disease) or liver and in patients undergoing treatment with other centrally acting medications or anticonvulsant (antiepileptic) agents (see section 4.5).
Clonazepam is considered to be probably nonporphyrinogenic at low doses, although there is some conflicting evidence of porphyrinogenicity at higher doses. Therefore, in patients with porphyria, clonazepam must be used with care.
Like all drugs of this type, Rivotril may, depending on dosage, administration and individual susceptibility, modify the patient's reactions (e.g. driving ability, behaviour in traffic).
In cases of loss or bereavement, psychological adjustment may be inhibited by benzodiazepines.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption, should not take this medicine.
Not recommended
In combination with Rivotril, alcohol may modify the effects of the drug, compromise the success of therapy or give rise to unpredictable side-effects (see also section 4.4).
Take into account
Centrally acting drugs: Enhanced effects on sedation, respiration and haemodynamics may occur when Rivotril is co-administered with any centrally acting depressants e.g. alcohol, and other anticonvulsant (antiepileptic) agents, anaesthetics, hypnotics, psychoactive drugs and some analgesics as well as muscle relaxants and may result in mutual potentiation of drug effects (see also section 4.9).
In combination therapy with centrally-acting medications, the dosage of each drug must be adjusted to achieve the optimum effect.
Antiepileptic drugs: When Rivotril is used in conjunction with other antiepileptic drugs, side-effects such as sedation and apathy, and toxicity may be more evident, particularly with hydantoins or phenobarbital and combinations including them. This requires extra care in adjusting dosage in the initial stages of treatment. The combination of Rivotril and sodium valproate has, rarely, been associated with the development of absence status epilepticus. Although some patients tolerate and benefit from this combination of drugs, this potential hazard should be borne in mind when its use is considered.
The antiepileptic drugs phenytoin, phenobarbital, carbamazepine and valproate may increase the clearance of clonazepam thereby decreasing the plasma concentrations of the latter during combined treatment.
Pharmacokinetic interactions: Clonazepam itself does not induce the enzymes responsible for its own metabolism.
The selective serotonin reuptake inhibitors sertraline and fluoxetine do not affect the pharmacokinetics of clonazepam when administered concomitantly.
Known inhibitors of hepatic enzymes, e.g. cimetidine, have been shown to reduce the clearance of benzodiazepines and may potentiate their action and known inducers of hepatic enzymes, e.g. rifampicin, may increase the clearance of benzodiazepines.
In concurrent treatment with phenytoin or primidone, a change, usually a rise in the serum concentration of these two substances has occasionally been observed.
Preclinical studies in animals have shown reproductive toxicity (see section 5.3 Preclinical safety data). From epidemiological evaluations there is evidence that anticonvulsant drugs act as teratogens.
Rivotril has harmful pharmacological effects on pregnancy and the foetus/newborn child. Administration of high doses in the last trimester of pregnancy or during labour can cause irregularities in the heart beat of the unborn child and hypothermia, hypotonia, mild respiratory depression and poor sucking in the neonate. Infants born to mothers who took benzodiazepines chronically during the later stages of pregnancy may have developed physical dependence and may be at some risk for developing withdrawal symptoms in the post-natal period. Therefore Rivotril should not be used in pregnancy unless clearly necessary.
The active ingredient of Rivotril has been found to pass into the maternal milk in small amounts. Therefore Rivotril should not be used in mothers who breastfeed unless clearly necessary.
As a general rule, epileptic patients are not allowed to drive. Even when adequately controlled on Rivotril, it should be remembered that any increase in dosage or alteration in timings of dosage may modify patients' reactions, depending on individual susceptibility. Even if taken as directed, clonazepam can slow reactions to such an extent that the ability to drive a vehicle or operate machinery is impaired. This effect is aggravated by consumption of alcohol. Driving, operating machinery and other hazardous activities should therefore be avoided altogether or at least during the first few days of treatment. The decision on this question rests with the patient's physician and should be based on the patient's response to treatment and the dosage involved.
The following have been observed:
Immune System Disorders
Allergic reactions and very few cases of anaphylaxis have been reported to occur with benzodiazepines. Angioedema may occur in rare cases.
Endocrine Disorders
Isolated cases of reversible development of premature secondary sex characteristics in children (incomplete precocious puberty) have been reported.
Psychiatric Disorders and Paradoxical Reactions
Impaired concentration, restlessness, confusional state, disorientation have been observed. Depression may occur in patients treated with Rivotril, but it may be also associated with the underlying disease.
The following paradoxical reactions have been observed: excitability, irritability, aggression, agitation, nervousness, hostility, anxiety, sleep disturbances, nightmares, vivid dreams and psychotic disorders and activation of new types of seizures may be precipitated. If these occur, the benefit of continuing the drug should be weighed against the adverse effect. The addition to the regimen of another suitable drug may be necessary or, in some cases, it may be advisable to discontinue Rivotril therapy.
Nervous System Disorders
Somnolence, slowed reaction, muscular hypotonia, dizziness and ataxia. These undesirable effects occur relatively frequently and may disappear gradually in the course of the treatment or on reduction of the dosage. They can be partially prevented by increasing the dose slowly at the start of treatment.
Headache was observed in rare cases.
Particularly in long-term or high-dose treatment, reversible disorders such as dysarthria, reduced coordination of movements and gait disorder (ataxia) and nystagmus may occur.
Anterograde amnesia may occur using benzodiazepines at therapeutic dosages, the risk increasing at higher dosages. Amnestic effects may be associated with inappropriate behaviour.
With certain forms of epilepsy, an increase in the frequency of seizures during long-term treatment is possible.
Although Rivotril has been given uneventfully to patients with porphyria, rarely it may induce convulsions in these patients.
Eye Disorders
Particularly in long-term or high-dose treatment, reversible disorders of vision (diplopia) may occur.
Cardiac Disorders
Cardiac failure including cardiac arrest has been reported.
Respiratory, Thoracic and Mediastinal System Disorders
Respiratory depression may occur, particularly on i.v. administration of clonazepam. This effect may be aggravated by pre-existing airways obstruction or brain damage or if other medications which depress respiration have been given. As a rule, this effect can be avoided by careful adjustment of the dose to individual requirements.
Increased salivation or bronchial secretion may occur in infants or young children (see also section 4.4).
Gastrointestinal Disorders
The following effects have been reported in rare cases: nausea and epigastric symptoms.
Skin and Subcutaneous Tissue Disorders
The following effects may occur in rare cases: urticaria, pruritus, rash, transient hair loss and pigmentation changes.
Musculoskeletal and Connective Tissue Disorders
Muscle weakness, this undesirable effect occurs relatively frequently and is usually transient and generally disappears spontaneously in the course of the treatment or on reduction of the dosage. It can be partially prevented by increasing the dose slowly at the start of treatment.
Renal and Urinary Disorders
In rare cases urinary incontinence may occur.
Reproductive System and Breast Disorders
In rare cases erectile dysfunction or loss of libido may occur.
General Disorders and Administration Site Conditions
Fatigue (tiredness, lassitude), this undesirable effect occurs relatively frequently and is usually transient and generally disappears spontaneously in the course of the treatment or on reduction of the dosage. It can be partially prevented by increasing the dose slowly at the start of treatment.
Injury, Poisoning and Procedural Complications
An increased risk for falls and fractures has been reported in elderly benzodiazepine users.
Investigations
In rare cases decreased platelet count may occur. As with other benzodiazepines, isolated cases of blood dyscrasias and abnormal liver function tests have been reported.
Dependence
Use of benzodiazepines may lead to the development of physical and psychological dependence upon these products. The risk of dependence increases with dose and duration of treatment; it is also greater in patients with a medical history of alcohol and/or drug abuse.
Once physical dependence has developed, abrupt termination of treatment will be accompanied by withdrawal symptoms. During long-term treatment, withdrawal symptoms may develop, especially with high doses or if the daily dose is reduced rapidly or abruptly discontinued. The symptoms include tremor, sweating, agitation, sleep disturbances and anxiety, headaches, muscle pain, extreme anxiety, tension, restlessness, confusion, irritability and epileptic seizures which may be associated with the underlying disease. In severe cases the following symptoms may occur: derealisation, depersonalisation, hyperacusis, numbness and tingling of the extremities, hypersensitivity to light, noise and physical contact or hallucinations. Since the risk of withdrawal symptoms is greater after abrupt discontinuation of treatment, abrupt withdrawal of the drug should therefore be avoided and treatment - even if only of short duration - should be terminated by gradually reducing the daily dose.
As with other benzodiazepine drugs, overdosage should not present undue problems of management or threat to life. Patients have recovered from overdoses in excess of 60mg without special treatment. Severe somnolence with muscle hypotonia will be present.
Symptoms:
The symptoms of overdosage or intoxication vary greatly from person to person depending on age, bodyweight and individual response. Benzodiazepines commonly cause drowsiness, ataxia, dysarthria and nystagmus. Overdose of Rivotril is seldom life-threatening if the drug is taken alone, but may lead to coma, areflexia, apnoea, hypotension and cardiorespiratory depression. Coma usually lasts a few hours but in elderly people it may be more protracted and cyclical. Benzodiazepine respiratory depressant effects are more serious in patients with severe chronic obstructive airways disease.
Benzodiazepines potentiate the effects of other central nervous system depressants, including alcohol.
Management:
1. Maintain a clear airway and adequate ventilation if indicated.
2. The benefit of gastric decontamination is uncertain. Consider activated charcoal (50g for an adult, 10-15g for a child) in adults or children who have taken more than 0.4mg/kg within 1 hour, provided they are not too drowsy.
3. Gastric lavage is unnecessary if these drugs have been taken alone.
4. Patients who are asymptomatic at 4 hours are unlikely to develop symptoms.
5. Supportive measures as indicated by the patient's clinical state. In particular, patients may require symptomatic treatment for cardiorespiratory effects or central nervous system effects.
6. Flumazenil (Anexate), a benzodiazepine antagonist is available but should rarely be required. It has a short half-life (about an hour). Flumazenil is NOT TO BE USED IN MIXED OVERDOSE OR AS A “DIAGNOSTIC TEST” (see separate prescribing information).
Warning
The use of flumazenil is not recommended in epileptic patients who have been receiving benzodiazepine treatment for a prolonged period. Although flumazenil exerts a slight intrinsic anticonvulsant effect, its abrupt suppression of the protective effect of a benzodiazepine agonist can give rise to convulsions in epileptic patients.
If excitation occurs, barbiturates should not be used.
Pharmacotherapeutic group: Benzodiazepine derivatives, ATC code: N03AE01.
Clonazepam exhibits pharmacological properties which are common to benzodiazepines and include anticonvulsive, sedative, muscle relaxing and anxiolytic effects. Animal data and electroencephalographic investigations in man have shown that clonazepam rapidly suppresses many types of paroxysmal activity including the spike and wave discharge in absence seizures (petit mal), slow spike wave, generalised spike wave, spikes with temporal or other locations as well as irregular spikes and waves.
Generalised EEG abnormalities are more readily suppressed by clonazepam than are focal EEG abnormalities such as focal spikes. Clonazepam has beneficial effects in generalised and focal epilepsies.
Absorption
Clonazepam is quickly and completely absorbed after oral administration of Rivotril. Peak plasma concentrations are reached in most cases within 1 - 4 hours after an oral dose. Bioavailability is 90% after oral administration.
Routine monitoring of plasma concentrations of Rivotril is of unproven value since this does not appear to correlate well with either therapeutic response or side-effects.
Distribution
The mean volume of distribution of clonazepam is estimated at about 3 l/kg. Clonazepam must be assumed to cross the placental barrier and has been detected in maternal milk.
Metabolism
The biotransformation of clonazepam involves oxidative hydroxylation and reduction of the 7-nitro group by the liver with formation of 7-amino or 7-acetylamino compounds, with trace amounts of 3-hydroxy derivatives of all three compounds, and their glucuronide and sulphate conjugates. The nitro compounds are pharmacologically active, whereas the amino compounds are not.
Elimination
The elimination half-life is between 20 and 60 hours (mean 30 hours).
Within 4 - 10 days 50 - 70% of the total radioactivity of a radiolabelled oral dose of clonazepam is excreted in the urine and 10 - 30% in the faeces, almost exclusively in the form of free or conjugated metabolites. Less than 0.5% appears as unchanged clonazepam in the urine.
Pharmacokinetics in special clinical situations
Based on kinetic criteria no dose adjustment is required in patients with renal failure.
Carcinogenicity
Conventional studies of carcinogenic potential have not been conducted with clonazepam. No 2-year carcinogenicity studies have been conducted with clonazepam. However, in an 18-month chronic study in rats no treatment-related histopathological changes were seen up to the highest tested dose of 300mg/kg/day.
Mutagenicity
Genotoxicity tests using bacterial systems with in vitro or host mediated metabolic activation did not indicate a genotoxic liability for clonazepam.
Impairment of Fertility
Studies assessing fertility and general reproductive performance in rats showed a reduced pregnancy rate and impaired pup survival at doses of 10 and 100mg/kg/day.
Teratogenicity
No adverse maternal or embryo-foetal effects were observed in either mice or rats following administration of oral clonazepam during organogenesis, at doses of up to 20 or 40mg/kg/day, respectively.
In several rabbit studies following doses of clonazepam of up to 20mg/kg/day, a low, non-dose-related incidence of a similar pattern of malformations (cleft palate, open eyelids, fused sternebrae and limb defects) was observed (see section 4.6).
As toxicokinetic evaluations have not been performed with clonazepam, it is not possible to determine the safety margin for the adverse effects observed in the non-clinical studies. The relevance of these findings to the patient population is unclear therefore a potential risk to man cannot be ruled out.
Rivotril 0.5mg tablets:
Lactose (monohydrate)
Maize starch
Pregelatinised potato starch
Talc
Magnesium stearate
Deionised water
Dye iron oxide red E172
Dye iron oxide yellow E172.
Rivotril 2mg tablets:
Lactose (anhydrous)
Pregelatinised maize starch
Magnesium stearate
Microcrystalline cellulose.
Not applicable.
5 years.
Store in the original container and in the outer carton, in order to protect from light.
Rivotril 0.5mg Tablets:
Amber glass bottles with polyethylene screw closures, containing 50, 100 or 150 tablets.
Rivotril 2mg Tablets:
Amber glass bottles with polyethylene screw closures, containing 30 or 100 tablets.
Not all pack sizes may be marketed.
There are no special instructions.
Any unused product or waste material should be disposed of in accordance with local requirements.
Roche Products Limited
6 Falcon Way
Shire Park
Welwyn Garden City
AL7 1TW
United Kingdom
|
|
|
|
26 July 1983/27 May 2005
11 October 2011
POM
Rivotril is a registered trade mark
Probecid may be available in the countries listed below.
Probenecid is reported as an ingredient of Probecid in the following countries:
International Drug Name Search
Cedoxyl may be available in the countries listed below.
Cefadroxil is reported as an ingredient of Cedoxyl in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
Rec.INN
D01AC03,G01AF05
0027220-47-9
C18-H15-Cl3-N2-O
381
Antifungal agent
1H-Imidazole, 1-[2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-
International Drug Name Search
Glossary
| BAN | British Approved Name |
| BANM | British Approved Name (Modified) |
| DCF | Dénomination Commune Française |
| DCIT | Denominazione Comune Italiana |
| IS | Inofficial Synonym |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Flutiderm may be available in the countries listed below.
Fluticasone propionate (a derivative of Fluticasone) is reported as an ingredient of Flutiderm in the following countries:
International Drug Name Search
Ergix toux sèche may be available in the countries listed below.
Dextromethorphan hydrobromide (a derivative of Dextromethorphan) is reported as an ingredient of Ergix toux sèche in the following countries:
International Drug Name Search
Retinide may be available in the countries listed below.
Isotretinoin is reported as an ingredient of Retinide in the following countries:
International Drug Name Search
Allopurinolo Molteni may be available in the countries listed below.
Allopurinol is reported as an ingredient of Allopurinolo Molteni in the following countries:
International Drug Name Search
In the US, Moban (molindone systemic) is a member of the drug class miscellaneous antipsychotic agents and is used to treat Psychosis and Schizophrenia.
US matches:
Molindone hydrochloride (a derivative of Molindone) is reported as an ingredient of Moban in the following countries:
International Drug Name Search
Terbinafine Qualimed may be available in the countries listed below.
Terbinafine hydrochloride (a derivative of Terbinafine) is reported as an ingredient of Terbinafine Qualimed in the following countries:
International Drug Name Search
In the US, Adderall XR (amphetamine/dextroamphetamine systemic) is a member of the drug class CNS stimulants and is used to treat ADHD and Narcolepsy.
US matches:
Amfetamine aspartate monohydrate and sulfate (a derivative of Amfetamine) is reported as an ingredient of Adderall XR in the following countries:
Dexamfetamine saccharate and sulfate (a derivative of Dexamfetamine) is reported as an ingredient of Adderall XR in the following countries:
International Drug Name Search
Betahistine ratiopharm may be available in the countries listed below.
Betahistine dihydrochloride (a derivative of Betahistine) is reported as an ingredient of Betahistine ratiopharm in the following countries:
International Drug Name Search
Prop.INN
N02AX01
0020380-58-9
C17-H23-N-O2
273
Opioid analgesic
3-Cyclohexene-1-carboxylic acid, 2-(dimethylamino)-1-phenyl-, ethyl ester, trans-(±)-
International Drug Name Search
Glossary
| BAN | British Approved Name |
| DCIT | Denominazione Comune Italiana |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Prop.INN | Proposed International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Xenthol may be available in the countries listed below.
Methyl Salicylate is reported as an ingredient of Xenthol in the following countries:
International Drug Name Search
Pepdul may be available in the countries listed below.
Famotidine is reported as an ingredient of Pepdul in the following countries:
International Drug Name Search
Apo-Floctafenine may be available in the countries listed below.
Floctafenine is reported as an ingredient of Apo-Floctafenine in the following countries:
International Drug Name Search
Permetrina may be available in the countries listed below.
Permethrin is reported as an ingredient of Permetrina in the following countries:
International Drug Name Search
Regaine may be available in the countries listed below.
UK matches:
Minoxidil is reported as an ingredient of Regaine in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
Epirubicin-Mepha may be available in the countries listed below.
Epirubicin hydrochloride (a derivative of Epirubicin) is reported as an ingredient of Epirubicin-Mepha in the following countries:
International Drug Name Search
Glucohexal may be available in the countries listed below.
Metformin hydrochloride (a derivative of Metformin) is reported as an ingredient of Glucohexal in the following countries:
International Drug Name Search
Momentact may be available in the countries listed below.
Ibuprofen is reported as an ingredient of Momentact in the following countries:
International Drug Name Search
Actilax may be available in the countries listed below.
Lactulose is reported as an ingredient of Actilax in the following countries:
Sodium Picosulfate is reported as an ingredient of Actilax in the following countries:
International Drug Name Search
Tatumcef may be available in the countries listed below.
Ceftazidime pentahydrate (a derivative of Ceftazidime) is reported as an ingredient of Tatumcef in the following countries:
International Drug Name Search
Pharmaniaga Simvastatin may be available in the countries listed below.
Simvastatin is reported as an ingredient of Pharmaniaga Simvastatin in the following countries:
International Drug Name Search
Acide orotique may be available in the countries listed below.
Acide orotique (DCF) is also known as Orotic Acid (Prop.INN)
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
| Prop.INN | Proposed International Nonproprietary Name (World Health Organization) |
Ascalix may be available in the countries listed below.
Piperazine citrate (a derivative of Piperazine) is reported as an ingredient of Ascalix in the following countries:
International Drug Name Search
Lévétiracétam may be available in the countries listed below.
Lévétiracétam (DCF) is known as Levetiracetam in the US.
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
Leflokin may be available in the countries listed below.
Levofloxacin hemihydrate (a derivative of Levofloxacin) is reported as an ingredient of Leflokin in the following countries:
International Drug Name Search
Minims Cyclopentolat Hydrochlorid may be available in the countries listed below.
Cyclopentolate hydrochloride (a derivative of Cyclopentolate) is reported as an ingredient of Minims Cyclopentolat Hydrochlorid in the following countries:
International Drug Name Search
Pectox may be available in the countries listed below.
Carbocisteine is reported as an ingredient of Pectox in the following countries:
International Drug Name Search
Calcipan may be available in the countries listed below.
Calcium Pantothenate is reported as an ingredient of Calcipan in the following countries:
International Drug Name Search
Capotril may be available in the countries listed below.
Captopril is reported as an ingredient of Capotril in the following countries:
International Drug Name Search
Céfatrizine Teva may be available in the countries listed below.
Cefatrizine comp. with propylene glycole (a derivative of Cefatrizine) is reported as an ingredient of Céfatrizine Teva in the following countries:
International Drug Name Search
Budesonide Target may be available in the countries listed below.
Budesonide is reported as an ingredient of Budesonide Target in the following countries:
International Drug Name Search
Ampliactil may be available in the countries listed below.
Chlorpromazine is reported as an ingredient of Ampliactil in the following countries:
International Drug Name Search
Ciplactin may be available in the countries listed below.
Cyproheptadine hydrochloride (a derivative of Cyproheptadine) is reported as an ingredient of Ciplactin in the following countries:
International Drug Name Search
Fermid may be available in the countries listed below.
Clomifene citrate (a derivative of Clomifene) is reported as an ingredient of Fermid in the following countries:
International Drug Name Search
Escaron may be available in the countries listed below.
Mefruside is reported as an ingredient of Escaron in the following countries:
International Drug Name Search
Isticol may be available in the countries listed below.
Chlorphenamine maleate (a derivative of Chlorphenamine) is reported as an ingredient of Isticol in the following countries:
International Drug Name Search
Etinoline may be available in the countries listed below.
Salbutamol sulfate (a derivative of Salbutamol) is reported as an ingredient of Etinoline in the following countries:
International Drug Name Search
Ephedrin Biotika may be available in the countries listed below.
Ephedrine hydrochloride (a derivative of Ephedrine) is reported as an ingredient of Ephedrin Biotika in the following countries:
International Drug Name Search
Levodopa-Benserazide may be available in the countries listed below.
Benserazide is reported as an ingredient of Levodopa-Benserazide in the following countries:
Levodopa is reported as an ingredient of Levodopa-Benserazide in the following countries:
International Drug Name Search
Rec.INN
S01EE05
0209860-87-7
C25-H34-F2-O5
452
Ophthalmic agent
(Z)-7-{(1R,2R,3R,5S)-2-[(E)-3,3-Difluor-4-phenoxybut-1-enyl]-3,5-dihydroxycyclopentyl}-hept-5-ensäureisopropylester (IUPAC)
Isopropyl (5Z)-7-{(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxybut-1-enyl]-3,5-dihydroxycyclopentyl}hept-5-enoate (WHO)
International Drug Name Search
Glossary
| IUPAC | International Union of Pure and Applied Chemistry |
| IS | Inofficial Synonym |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| WHO | World Health Organization |
Tamoxifeno Elfar may be available in the countries listed below.
Tamoxifen citrate (a derivative of Tamoxifen) is reported as an ingredient of Tamoxifeno Elfar in the following countries:
International Drug Name Search
Mitomycin-C may be available in the countries listed below.
Mitomycin is reported as an ingredient of Mitomycin-C in the following countries:
International Drug Name Search
Longes may be available in the countries listed below.
Lisinopril is reported as an ingredient of Longes in the following countries:
International Drug Name Search
Biozamina may be available in the countries listed below.
Glucosamine hydrochloride (a derivative of Glucosamine) is reported as an ingredient of Biozamina in the following countries:
International Drug Name Search
Praux may be available in the countries listed below.
Metoclopramide hydrochloride (a derivative of Metoclopramide) is reported as an ingredient of Praux in the following countries:
International Drug Name Search
Augmex may be available in the countries listed below.
Amoxicillin is reported as an ingredient of Augmex in the following countries:
Amoxicillin trihydrate (a derivative of Amoxicillin) is reported as an ingredient of Augmex in the following countries:
Clavulanic Acid is reported as an ingredient of Augmex in the following countries:
Clavulanic Acid potassium (a derivative of Clavulanic Acid) is reported as an ingredient of Augmex in the following countries:
International Drug Name Search
Foligan may be available in the countries listed below.
Allopurinol is reported as an ingredient of Foligan in the following countries:
International Drug Name Search
Jasocal may be available in the countries listed below.
Calcium Carbonate is reported as an ingredient of Jasocal in the following countries:
International Drug Name Search
